Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials

Vito Di Marco, Susanna Caronia, Angelo Andriulli, Alessandra Mangia, Gioacchino Leandro, Eberhard L. Renner, Stephan Zeuzem, Graham R. Foster, Thomas Berg, Simona Caronia, Laura Sidoli, Marco Tabone, Beat Helbling

Risultato della ricerca: Article

37 Citazioni (Scopus)

Abstract

Background/Aims: In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods: Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre-treatment interaction fitted as random variables. Results: At the end of therapy, virological responses were 38.5% (95% CI 34.1-42.8) after INF and AMA, and 29.5% (95% CI 25.5-33.6) after INF alone (P = 0.003). Sustained response occurred in 111 (23.1%; 95% CI 19.3-20.2) and 85 patients (17.3%; 95% CI 14.0-20.7), respectively (P = 0.03). Even accounting for the centre effect, therapy with AMA and INF was more effective than IFN alone (P = 0.029). When genotypes and viraemia levels were combined, the response rate after combination therapy doubled that observed with IFN alone in all subgroups, except those with low viraemia and genotypes 2 or 3. Conclusions: In chronic hepatitis C, therapy with AMA and INF is effective and may be an alternative to INF and ribavirin in patients who cannot tolerate ribavirin.
Lingua originaleEnglish
pagine (da-a)478-483
Numero di pagine6
RivistaJournal of Hepatology
Volume40
Stato di pubblicazionePublished - 2004

All Science Journal Classification (ASJC) codes

  • Hepatology

Cita questo

Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. / Di Marco, Vito; Caronia, Susanna; Andriulli, Angelo; Mangia, Alessandra; Leandro, Gioacchino; Renner, Eberhard L.; Zeuzem, Stephan; Foster, Graham R.; Berg, Thomas; Caronia, Simona; Sidoli, Laura; Tabone, Marco; Helbling, Beat.

In: Journal of Hepatology, Vol. 40, 2004, pag. 478-483.

Risultato della ricerca: Article

Di Marco, V, Caronia, S, Andriulli, A, Mangia, A, Leandro, G, Renner, EL, Zeuzem, S, Foster, GR, Berg, T, Caronia, S, Sidoli, L, Tabone, M & Helbling, B 2004, 'Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials', Journal of Hepatology, vol. 40, pagg. 478-483.
Di Marco, Vito ; Caronia, Susanna ; Andriulli, Angelo ; Mangia, Alessandra ; Leandro, Gioacchino ; Renner, Eberhard L. ; Zeuzem, Stephan ; Foster, Graham R. ; Berg, Thomas ; Caronia, Simona ; Sidoli, Laura ; Tabone, Marco ; Helbling, Beat. / Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. In: Journal of Hepatology. 2004 ; Vol. 40. pagg. 478-483.
@article{a41ac25b98ee488fb15074eb93da3a46,
title = "Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials",
abstract = "Background/Aims: In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods: Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre-treatment interaction fitted as random variables. Results: At the end of therapy, virological responses were 38.5{\%} (95{\%} CI 34.1-42.8) after INF and AMA, and 29.5{\%} (95{\%} CI 25.5-33.6) after INF alone (P = 0.003). Sustained response occurred in 111 (23.1{\%}; 95{\%} CI 19.3-20.2) and 85 patients (17.3{\%}; 95{\%} CI 14.0-20.7), respectively (P = 0.03). Even accounting for the centre effect, therapy with AMA and INF was more effective than IFN alone (P = 0.029). When genotypes and viraemia levels were combined, the response rate after combination therapy doubled that observed with IFN alone in all subgroups, except those with low viraemia and genotypes 2 or 3. Conclusions: In chronic hepatitis C, therapy with AMA and INF is effective and may be an alternative to INF and ribavirin in patients who cannot tolerate ribavirin.",
author = "{Di Marco}, Vito and Susanna Caronia and Angelo Andriulli and Alessandra Mangia and Gioacchino Leandro and Renner, {Eberhard L.} and Stephan Zeuzem and Foster, {Graham R.} and Thomas Berg and Simona Caronia and Laura Sidoli and Marco Tabone and Beat Helbling",
year = "2004",
language = "English",
volume = "40",
pages = "478--483",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",

}

TY - JOUR

T1 - Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials

AU - Di Marco, Vito

AU - Caronia, Susanna

AU - Andriulli, Angelo

AU - Mangia, Alessandra

AU - Leandro, Gioacchino

AU - Renner, Eberhard L.

AU - Zeuzem, Stephan

AU - Foster, Graham R.

AU - Berg, Thomas

AU - Caronia, Simona

AU - Sidoli, Laura

AU - Tabone, Marco

AU - Helbling, Beat

PY - 2004

Y1 - 2004

N2 - Background/Aims: In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods: Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre-treatment interaction fitted as random variables. Results: At the end of therapy, virological responses were 38.5% (95% CI 34.1-42.8) after INF and AMA, and 29.5% (95% CI 25.5-33.6) after INF alone (P = 0.003). Sustained response occurred in 111 (23.1%; 95% CI 19.3-20.2) and 85 patients (17.3%; 95% CI 14.0-20.7), respectively (P = 0.03). Even accounting for the centre effect, therapy with AMA and INF was more effective than IFN alone (P = 0.029). When genotypes and viraemia levels were combined, the response rate after combination therapy doubled that observed with IFN alone in all subgroups, except those with low viraemia and genotypes 2 or 3. Conclusions: In chronic hepatitis C, therapy with AMA and INF is effective and may be an alternative to INF and ribavirin in patients who cannot tolerate ribavirin.

AB - Background/Aims: In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods: Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre-treatment interaction fitted as random variables. Results: At the end of therapy, virological responses were 38.5% (95% CI 34.1-42.8) after INF and AMA, and 29.5% (95% CI 25.5-33.6) after INF alone (P = 0.003). Sustained response occurred in 111 (23.1%; 95% CI 19.3-20.2) and 85 patients (17.3%; 95% CI 14.0-20.7), respectively (P = 0.03). Even accounting for the centre effect, therapy with AMA and INF was more effective than IFN alone (P = 0.029). When genotypes and viraemia levels were combined, the response rate after combination therapy doubled that observed with IFN alone in all subgroups, except those with low viraemia and genotypes 2 or 3. Conclusions: In chronic hepatitis C, therapy with AMA and INF is effective and may be an alternative to INF and ribavirin in patients who cannot tolerate ribavirin.

UR - http://hdl.handle.net/10447/29054

M3 - Article

VL - 40

SP - 478

EP - 483

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -